Observations placeholder
Anastrazole and Arimidex
Identifier
017646
Type of Spiritual Experience
Background
A description of the experience
Anastrozole (marketed under the trade name Arimidex ) is a non-steroidal aromatase-inhibiting drug approved for treatment of breast cancer after surgery, as well as for metastasis in both pre and post-menopausal women. The severity of breast cancer can be increased by estrogen, as sex hormones cause hyperplasia, and differentiation at estrogen receptor sites. Anastrozole inhibits the synthesis of estrogen.
Anastrozole has been tested for reducing estrogens, including estradiol, in men. Excess estradiol in men can cause benign prostatic hyperplasia, gynecomastia, and symptoms of hypogonadism. Study data suggests dosages of 0.5 mg to 1 mg a day reduce serum estradiol by approximately 50% in men, which differs in postmenopausal women
On Jan, 02, 2017 3,874 people reported to have side effects when taking Anastrozole.
Among them, 79 people (2.04%) have Death
Time on Anastrozole when people have Death :
< 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
Death | 0.00% | 0.00% | 25.00% | 0.00% | 75.00% | 0.00% | 0.0 |
On Dec, 29, 2016 16,488 people reported to have side effects when taking Arimidex.
Among them, 622 people (3.77%) have Death
Time on Arimidex when people have Death :
< 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
Death | 2.86% | 11.43% | 2.86% | 34.29% | 45.71% | 2.86% | 0.00% |
On Dec, 26, 2016 3,874 people reported to have side effects when taking Anastrozole. Among them, 17 people (0.44%) have Hallucination
On Jan, 17, 2017 16,488 people reported to have side effects when taking Arimidex.
Among them, 62 people (0.38%) have Hallucination
Time on Arimidex when people have Hallucination :
< 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
Hallucination | 0.00% | 50.00% | 50.00% | 0.00% | 0.00% | 0.00% | 0.00% |